First Patient Dosed in Clinical Development Program for KSQ-001EX
“TIL have emerged as a powerful new treatment modality, and we believe both of our eTIL® programs, KSQ-001EX and KSQ-004EX, have the potential to significantly advance the field by improving the potency of TIL therapy for the treatment of a variety of solid tumor types. In preclinical studies, KSQ-001EX demonstrated enhanced anti-tumor activity, polyclonality, persistence, and memory formation in multiple solid tumor models compared to unmodified TIL. We also saw robust anti-tumor activity in models insensitive to PD-1 inhibition,” said Qasim Rizvi, Chief Executive Officer of KSQ. “We look forward to evaluating KSQ-001EX in patients with difficult-to-treat solid tumors, including melanoma, head and neck squamous cell carcinoma, and non-small cell lung cancer.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo